Contract testing and manufacturing services to
support development through commercialization

Tissue cross reactivity is the unintended reaction of therapeutic monoclonal antibodies with tissues and proteins other than the target antigen.  The FDA recommends pre-clinical testing cross reactivity studies in a range of tissues by immunohistochemistry.

BioReliance offers a proven team of histologists ready to analyze cross reactivity for your therapeutic monoclonal.  Typically tissue cross reactivity is performed in frozen human tissues under GLP conditions.

BioReliance has extensive experience developing both immunocytochemical and immunohistochemical assays for many applications including the detection of biomarker expression in cellular and tissue specimens and tissue cross reactivity studies for the development of monoclonal antibody therapeutics.

Contact a BioReliance scientist to find the tissue cross reactivity studies you need by clicking here.

Why does tissue cross reactivity happen?

Monoclonal antibody therapeutics are selected for the ability to bind critical epitopes or protein configurations on target antigens.  Since many antigens are “foreign”, meaning they come from infectious diseases or cancerous proteins, the possibility exists the epitope targeted exists naturally within a patient.  The end result being cross reactivity with the foreign agent and normal protein in the patient.  Of course, tissue cross reactivity studies are designed to prevent this from happening.

BioReliance is one of the world’s leading CROs with decades of experience supporting pre-clinical evaluation of biologicals and tissue cross reactivity studies.